SLC5A2 and diabetic kidney disease: For treatment of diabetic nephropathy to slow down CKD progression, angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), and the sodium-glucose cotransporter 2 inhibitors (SGLT-2is) are approved.